BG-A3004

Phase 1Biologic

BBeOne Medicines

BG-A3004 is one of 2 biologic programs targeting Skin Diseases. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Skin DiseasesRecruiting

Skin DiseasesPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Skin Diseases

#DrugCompanyPhaseTrials

BG-A3004

BBeOne Medicines

Phase 1

1 2

Diphenylcyclopropenone

RRockefeller University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Skin Diseases

NCT07412691

Clinical

Trials by Indication[1]

Skin Diseases1 trial

A Phase 1, Randomized, Double-Blind, Placebo Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases

Recruiting·BBeOne Medicines·Phase 1·NCT07412691·98 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BG-A3004. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BG-A3004 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BG-A3004. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeOne Medicines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: BBeOne Medicines

BG-A3004

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Skin Diseases1 trial

References

Drug Info

Quick Facts

Related News